HLA-E and acute myeloid leukemia: For example, the pan-CDK inhibitor, dinaciclib, which recently completed phase II clinical testing in AML (NCT03484520), reduces surface expression of HLA-E on AML cell lines and on primary AML cells, and promotes NK cell activation [124].